Literature DB >> 31584500

Open Mastoid Cavity Obliteration With a High-Porosity Hydroxyapatite Ceramic Leads to High Rate of Revision Surgery and Insufficient Cavity Obliteration.

Nora M Weiss1, Sophie Stecher1, David Bächinger2, Tobias Schuldt1, Sönke Langner3, Sarah Zonnur4, Robert Mlynski1, Sebastian P Schraven1.   

Abstract

OBJECTIVE: To assess long-term results and present experience with a high-porosity hydroxyapatite ceramic for obliterating large open mastoid cavities. STUDY-
DESIGN: Cross-sectional cohort study.
SETTING: Tertiary academic referral center. PATIENTS: All patients who underwent tympanomastoid surgery for chronic middle ear disease or revision surgery with reduction of an open mastoid cavity using a highly porous hydroxyapatite matrix material (HMM) between May 2005 and June 2013 were assessed for eligibility. Twenty three patients (56.9 ± 18.3 yr) were included. INTERVENTION: Primary middle ear surgery or revision surgery using a HMM. MAIN OUTCOME MEASURES: Pure-tone average, computed tomography (CT), and magnetic resonance imaging (MRI) to investigate osseoinduction, osseointegration and presence of cholesteatoma, current quality of life assessed by Zurich Chronic Middle Ear Inventory and change in quality of life post-intervention assessed by the Glasgow Benefit Inventory.
RESULTS: Patients were reexamined after a mean follow-up period of 88.3 months (SD 21.4 mo) after obliteration of the open mastoid cavity with HMM. Compared with visit 1, patients showed a significantly reduced ABG at visit 2 (29.22 dB ± 2.71 dB versus 12.77 dB ± 3.46 dB).CT scan was carried out in 21 patients (91%) patients and 17 patients (74%) underwent MRI.Revision surgery was required in a total of 17 cases (74%). In four patients recurrent cholesteatoma was found at follow up.
CONCLUSIONS: Poor cavity obliteration, a high rate of revision surgery and difficult differentiation between recurrent cholesteatoma and granulation tissue in CT scan was observed.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31584500     DOI: 10.1097/MAO.0000000000002413

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  6 in total

1.  Mid-term outcomes of mastoid obliteration with biological hydroxyapatite versus bioglass: a radiological and clinical study.

Authors:  Sonia Sahli-Vivicorsi; Zarrin Alavi; William Bran; Romain Cadieu; Philippe Meriot; Jean-Christophe Leclere; Rémi Marianowski
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-01-17       Impact factor: 3.236

2.  Antibiotics in mastoid and epitympanic obliteration with S53P4 bioactive glass: A retrospective study.

Authors:  Lauranne Alciato; Daniele Bernardeschi; Valérie Pourcher; Naira Mkrtchyan; Frédéric Tankéré; Olivier Sterkers; Ghizlène Lahlou
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-09-14

3.  Outcomes of a novel alloplastic technique for external auditory canal repair in tympanomastoidectomy.

Authors:  Karissa L LeClair; Sarah Y Bessen; Christiaan A Rees; James E Saunders
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-08-04

4.  Establishing the minimal clinically important difference (MCID) of the Zurich Chronic Middle Ear Inventory (ZCMEI-21) in patients treated for chronic middle ear disease.

Authors:  David Bächinger; Robert Mlynski; Nora M Weiss
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-01-27       Impact factor: 2.503

5.  Mastoid cavity obliteration leads to a clinically significant improvement in health-related quality of life.

Authors:  Nora M Weiss; David Bächinger; Jannik Botzen; Wilma Großmann; Robert Mlynski
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-03-06       Impact factor: 2.503

6.  Mapping the ChOLE classification to hearing outcomes and disease-specific health-related quality of life.

Authors:  Nora M Weiss; David Bächinger; Adrian Rrahmani; Hans E Bernd; Alexander Huber; Robert Mlynski; Christof Röösli
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-05-05       Impact factor: 2.503

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.